Advertisement
Product › Details
Lu AE58054
Next higher product group | 5-HT6 receptor antagonist | |
Status | 2012-05-29 development pc existent | |
Organisation | H. Lundbeck A/S | |
Group | Lundbeck (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for CNS drug (neurological drug)
- [1] Engrail Therapeutics, Inc.. (3/19/24). "Press Release: Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies". San Diego, CA....
- [2] Sosei Group Corporation (d/b/a Sosei Heptares). (3/11/24). "Press Release: Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-in-class Treatments Targeting All Symptoms of Schizophrenia". Ingelheim, Tokyo & Cambridge....
- [3] Bristol Myers Squibb Company. (12/22/23). "Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics". Princeton, N.J. & Boston, MA....
- [4] Vandria S.A.. (12/14/23). "Press Release: Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform". Lausanne....
- [5] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
- [6] Autifony Therapeutics Ltd.. (11/14/23). "Press Release: Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders". Stevenage....
- [7] VectorY Therapeutics B.V.. (11/13/23). "Press Release: VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases". Amsterdam....
- [8] Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden....
- [9] Argobio S.A.S.. (9/25/23). "Press Release: Northern Gritstone and Argobio Studio Back Sheffield University Spin-out Crucible Therapeutics". Paris, Manchester & Sheffield....
- [10] Secarna Pharmaceuticals GmbH & Co. KG. (3/27/23). "Press Release: Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of CNS Diseases". Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top